Form 4 Filing for Karlin Daniel

Daniel Karlin, Chief Medical Officer and Director of Definium Therapeutics, Inc. (DFTX), reported a sale of 10,853 common shares on September 25, 2026. The sale was conducted under a Rule 10b5-1 plan to cover withholding tax obligations related to the settlement of vested restricted stock units. The shares were sold at a weighted average price of $36.57, with individual transactions ranging from $36.24 to $36.98. Following this transaction, Karlin Daniel holds 792,846 common shares. The filing was made on September 29, 2026.